# PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)

> **NCT04754061** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- Depression, Anxiety
- Distress, Emotional

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT04754061
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-08
- **Primary completion:** 2025-01
- **Final completion:** 2025-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04754061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04754061, "PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04754061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*